Effects of synthetic human pancreatic (tumor) GH releasing factor and somatostatin, triiodothyronine and dexamethasone on GH secretion in vitro
W VALE, J VAUGHAN, G YAMAMOTO, J SPIESS… - …, 1983 - academic.oup.com
W VALE, J VAUGHAN, G YAMAMOTO, J SPIESS, J RIVIER
Endocrinology, 1983•academic.oup.comThe effects of synthetic human pancreatic (tumor) GH Releasing Factor, hpGRF, and a
partially purified rat hypothalamic GRF, rhGRF, on secretion of GH by primary cultures of rat
pituitary cells are reported to be inhibited noncompetitively by somatostatin. Dexamethasone
and triiodothyronine pretreatment enhance the response to hpGRF.
partially purified rat hypothalamic GRF, rhGRF, on secretion of GH by primary cultures of rat
pituitary cells are reported to be inhibited noncompetitively by somatostatin. Dexamethasone
and triiodothyronine pretreatment enhance the response to hpGRF.
The effects of synthetic human pancreatic (tumor) GH Releasing Factor, hpGRF, and a partially purified rat hypothalamic GRF, rhGRF, on secretion of GH by primary cultures of rat pituitary cells are reported to be inhibited noncompetitively by somatostatin. Dexamethasone and triiodothyronine pretreatment enhance the response to hpGRF.
Oxford University Press